Development and validation of the mini Rhinoconjunctivitis Quality of Life Questionnaire
- PMID: 10606940
- DOI: 10.1046/j.1365-2222.2000.00668.x
Development and validation of the mini Rhinoconjunctivitis Quality of Life Questionnaire
Abstract
Background: The 28-item Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) has strong measurement properties but for large clinical trials, surveys and practice monitoring, where high efficiency is important, a shorter questionnaire is needed.
Objective: To develop and validate an abbreviated version of the RQLQ.
Methods: Using five RQLQ databases, items with high item-item correlations were combined and then the highest scoring items were selected for the MiniRQLQ (14 questions). There are five domains: activity limitations (standardized), practical problems and nose symptoms, eye symptoms and other symptoms. The MiniRQLQ, which is self-administered, was tested in a 5-week observational study in 100 adults with symptomatic rhinoconjunctivitis. Patients completed the MiniRQLQ, the RQLQ, and other measures of health status at baseline, 1 and 5 weeks.
Results: In patients whose rhinoconjunctivitis was stable between clinic visits, reliability (reproducibility and ability to discriminate between patients of different impairment) was very acceptable for the MiniRQLQ (ICC = 0.93) but not quite as good as for the RQLQ (ICC = 0.97). Responsiveness to change in clinical status was better with the MiniRQLQ than the RQLQ (P = 0. 044). Construct validity (correlation with other indices of health status) was strong for both the MiniRQLQ and the RQLQ. Concordance between the two instruments was high (ICC = 0.87).
Conclusions: The MiniRQLQ has strong measurement properties and measures the same construct as the original RQLQ. The choice of questionnaire should depend on the task at hand.
Similar articles
-
Validation of the standardized version of the Rhinoconjunctivitis Quality of Life Questionnaire.J Allergy Clin Immunol. 1999 Aug;104(2 Pt 1):364-9. doi: 10.1016/s0091-6749(99)70380-5. J Allergy Clin Immunol. 1999. PMID: 10452758
-
Can the standard gamble and rating scale be used to measure quality of life in rhinoconjunctivitis? Comparison with the RQLQ and SF-36.Allergy. 2002 Mar;57(3):201-6. doi: 10.1034/j.1398-9995.2002.1o3306.x. Allergy. 2002. PMID: 11906333
-
Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis.Clin Exp Allergy. 1991 Jan;21(1):77-83. doi: 10.1111/j.1365-2222.1991.tb00807.x. Clin Exp Allergy. 1991. PMID: 2021881 Clinical Trial.
-
[Validation of the Spanish version of the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ)].Rev Clin Esp. 2004 Mar;204(3):131-8. doi: 10.1157/13058825. Rev Clin Esp. 2004. PMID: 15025979 Spanish.
-
Allergic rhinoconjunctivitis--an overview.Acta Ophthalmol Scand Suppl. 2000;(230):66-8. doi: 10.1034/j.1600-0420.2000.078s230066.x. Acta Ophthalmol Scand Suppl. 2000. PMID: 11057356 Review. No abstract available.
Cited by
-
Effects of Serum Vitamin D and Efficacy of Subcutaneous Immunotherapy in Adult Patients With Allergic Rhinitis.Allergy Asthma Immunol Res. 2019 Nov;11(6):885-893. doi: 10.4168/aair.2019.11.6.885. Allergy Asthma Immunol Res. 2019. PMID: 31552722 Free PMC article.
-
A novel and alternative therapy for persistent allergic rhinitis via intranasal acupuncture: a randomized controlled trial.Eur Arch Otorhinolaryngol. 2023 Jun;280(6):2773-2783. doi: 10.1007/s00405-022-07793-x. Epub 2023 Jan 9. Eur Arch Otorhinolaryngol. 2023. PMID: 36617611 Free PMC article. Clinical Trial.
-
Development and implementation of a nurse-led allergy clinic model in primary care: feasibility trial protocol.NPJ Prim Care Respir Med. 2019 Dec 6;29(1):44. doi: 10.1038/s41533-019-0155-5. NPJ Prim Care Respir Med. 2019. PMID: 31811151 Free PMC article. Review.
-
The Clinical Significance of Pollen and Fungi Concentrations for Allergic Rhinitis: A Three-Year Study.Cureus. 2023 Jun 14;15(6):e40397. doi: 10.7759/cureus.40397. eCollection 2023 Jun. Cureus. 2023. PMID: 37456499 Free PMC article.
-
Montelukast as add-on therapy with inhaled corticosteroids alone or inhaled corticosteroids and long-acting beta-2-agonists in the management of patients diagnosed with asthma and concurrent allergic rhinitis (the RADAR trial).Can Respir J. 2009 May-Jun;16 Suppl A(Suppl A):17A-31A. doi: 10.1155/2009/145071. Can Respir J. 2009. PMID: 19557208 Free PMC article. Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical